Tuesday, May 27, 2008 5:31:00 AM PDT | VentureDeal Staff
HyperMed is applying hyperspectral technology to medical applications via its flagship diagnostic device, the OxyVu-1, which has received FDA clearance for use in assessing patients for poor tissue circulation.
GBP Capital made the investment. The company said the proceeds would be used to support its ongoing marketing and sales initiatives of its lead product.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
